Form 8-K - Current report:
SEC Accession No. 0001564590-20-050562
Filing Date
2020-11-04
Accepted
2020-11-04 17:00:39
Documents
15
Period of Report
2020-11-04
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K onct-8k_20201104.htm   iXBRL 8-K 38790
2 EX-99.1 onct-ex991_6.htm EX-99.1 201522
3 GRAPHIC gmcobsdwej3y000002.jpg GRAPHIC 3681
4 GRAPHIC gmcobsdwej3y000001.jpg GRAPHIC 7888
  Complete submission text file 0001564590-20-050562.txt   399401

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA onct-20201104.xsd EX-101.SCH 5780
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE onct-20201104_lab.xml EX-101.LAB 19466
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE onct-20201104_pre.xml EX-101.PRE 11635
8 EXTRACTED XBRL INSTANCE DOCUMENT onct-8k_20201104_htm.xml XML 3570
Mailing Address 12230 EL CAMINO REAL SUITE 300 SAN DIEGO CA 92130
Business Address 12230 EL CAMINO REAL SUITE 300 SAN DIEGO CA 92130 (858) 434-1113
Oncternal Therapeutics, Inc. (Filer) CIK: 0001260990 (see all company filings)

EIN.: 621715807 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-50549 | Film No.: 201287426
SIC: 2834 Pharmaceutical Preparations